NCT04144023 2026-03-05
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
Phase 1 Recruiting
Clinical Trials
20 trialsNCT03879694 2026-02-06
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT05421897 2026-01-29
RAPID
Children's Hospital Los Angeles
Phase 1 Active not recruiting
NCT05307835 2025-12-02
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Active not recruiting
NCT00669734 2025-10-24
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02334865 2025-05-11
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Roswell Park Cancer Institute
Phase 1 Active not recruiting
NCT00436254 2025-04-06
Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer
University of Washington
Phase 1 Completed
NCT02780401 2024-09-19
WOKVAC
University of Washington
Phase 1 Completed
NCT02444546 2023-04-24
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Mayo Clinic
Phase 1 Completed
NCT03645148 2021-11-16
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer
Zhejiang Provincial People's Hospital
Phase 1 Completed
NCT03662815 2021-11-16
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor
Sir Run Run Shaw Hospital
Phase 1 Unknown
NCT04810910 2021-11-16
Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
Zhejiang Provincial People's Hospital
Phase 1 Unknown
NCT04864379 2021-04-28
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors
Sir Run Run Shaw Hospital
Phase 1 Unknown
NCT00064129 2020-07-30
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00470015 2019-02-19
Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV Melanoma
Mayo Clinic
Phase 1 Completed
NCT01250470 2017-02-27
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Roswell Park Cancer Institute
Phase 1 Completed
NCT00027807 2016-02-17
Biological Therapy in Treating Women With Stage IV Breast Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT02470559 2016-02-17
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT00217373 2015-04-20
Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
National Cancer Institute (NCI)
Phase 1 Completed
NCT01403285 2014-05-19
Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma
Immatics Biotechnologies GmbH
Phase 1 Terminated